EMC Capital Management Invests $154,000 in LivaNova PLC $LIVN

EMC Capital Management purchased a new stake in LivaNova PLC (NASDAQ:LIVN) in the second quarter, HoldingsChannel reports. The firm purchased 3,420 shares of the company’s stock, valued at approximately $154,000.

Several other institutional investors have also recently bought and sold shares of LIVN. GAMMA Investing LLC lifted its holdings in LivaNova by 182.5% during the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after buying an additional 407 shares in the last quarter. CWM LLC increased its stake in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after buying an additional 299 shares during the period. Parallel Advisors LLC raised its position in shares of LivaNova by 1,312.3% during the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock worth $46,000 after acquiring an additional 958 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock valued at $58,000 after acquiring an additional 1,184 shares during the period. Finally, Strs Ohio bought a new position in LivaNova in the first quarter valued at about $130,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of NASDAQ:LIVN opened at $53.89 on Wednesday. The firm’s 50 day simple moving average is $53.52 and its 200 day simple moving average is $49.25. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of -13.85 and a beta of 1.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.91 by $0.20. The firm had revenue of $357.80 million during the quarter, compared to the consensus estimate of $342.32 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.90 earnings per share. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, sell-side analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on LIVN shares. Robert W. Baird boosted their price objective on LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research note on Wednesday, September 3rd. Mizuho increased their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.43.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.